tbuckley/cabot-search huggingface dataset:
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID‐19 Pandemic: Version 3
Authors: Ted R. Mikuls, Sindhu R. Johnson, Liana Fraenkel, Reuben J. Arasaratnam, Lindsey R. Baden, Bonnie L. Bermas, Winn Chatham, Stanley Cohen, Karen Costenbader, Ellen M. Gravallese, Andre C. Kalil, Michael E. Weinblatt, Kevin Winthrop, Amy S. Mudano, Amy Turner, Kenneth G. Saag
Journal: Arthritis & Rheumatology (2020)

To provide guidance to rheumatology providers on the management of adult rheumatic disease in the context of the coronavirus disease 2019 (COVID-19) pandemic.A task force, including 10 rheumatologists and 4 infectious disease specialists from North America, was convened. Clinical questions were collated, and an evidence report was rapidly generated and disseminated. Questions and drafted statements were reviewed and assessed using a modified Delphi process. This included asynchronous anonymous voting by email and webinars with the entire panel. Task force members voted on agreement with draft statements using a 1-9-point numerical scoring system, and consensus was determined to be low, moderate, or high based on the dispersion of votes. For approval, median votes were required to meet predefined levels of agreement (median values of 7-9, 4-6, and 1-3 defined as agreement, uncertainty, or disagreement, respectively) with either moderate or high levels of consensus.Draft guidance statements approved by the task force have been combined to form final guidance.These guidance statements are provided to promote optimal care during the current pandemic. However, given the low level of available evidence and the rapidly evolving literature, this guidance is presented as a "living document," and future updates are anticipated.
Regional Distribution of Fluorine-18-Flubrobenguane and Carbon-11-Hydroxyephedrine for Cardiac PET Imaging of Sympathetic Innervation
Authors: Jason G.E. Zelt, Deron Britt, Braeden A. Mair, Benjamin H. Rotstein, Sarah Quigley, Olga Walter, Linda Garrard, Simon Robinson, Lisa M. Mielniczuk, Robert A. deKemp, Rob S. Beanlands
Journal: JACC. Cardiovascular imaging (2020)
Aberrant HCK Survival Signaling By Mutated MYD88 Requires PAX5 in Waldenstrom's Macroglobulinemia and ABC DLBCL Cells
Authors: Xia Liu, Jiaji Chen, Manit Munshi, Lian Xu, Nickolas Tsakmaklis, Maria Demos, Amanda Kofides, Maria Luisa Guerrera, Gloria Chan, Christopher Patterson, Joshua Gustine, Jorge J. Castillo, Zachary Hunter, Steven P Treon, Guang Yang
Journal: Blood (2017)
Scientific divisions on covid-19: time for open debate
Authors: Thomas Scanlon
Journal: BMJ (2020)

<h3>Background</h3> Prior studies have reported that patients with epilepsy have a higher prevalence of obstructive sleep apnea (OSA) that contributes to poor seizure control. Detection and treatment of OSA can improve seizure control in some patients with epilepsy. In this study, we sought to develop, implement, and evaluate the effectiveness of an electronic health record (EHR) alert to screen for OSA in patients with epilepsy. <h3>Methods</h3> A 3-month retrospective chart review was conducted of all patients with epilepsy &gt;18 years of age who were evaluated in our epilepsy clinics prior to the intervention. An assessment for obstructive sleep apnea (AOSA) consisting of 12 recognized risk factors for OSA was subsequently developed and embedded in the EHR. The AOSA was utilized for a 3-month period. Patients identified with 2 or more risk factors were referred for polysomnography. A comparison was made to determine if there was a difference in the number of patients at risk for OSA detected and referred for polysomnography with and without an EHR alert to screen for OSA. <h3>Results</h3> There was a significant increase in OSA patient recognition. Prior to the EHR alert, 25/346 (7.23%) patients with epilepsy were referred for a polysomnography. Postintervention, 405/414 patients were screened using an EHR alert for AOSA and 134/405 (33.1%) were referred for polysomnography (<i>p</i> &lt; 0.001). <h3>Conclusion</h3> An intervention with AOSA cued in the EHR demonstrated markedly improved identification of epilepsy patients at risk for OSA and referral for polysomnography.
Absence of SARS-CoV-2 antibodies in health care workers of a tertiary referral hospital for COVID-19 in southern Vietnam
Authors: Nguyen Van Vinh Chau, Le Mau Toan, Dinh Nguyen Huy Man, Huynh Phuong Thao, Nguyen Phu Huong Lan, Dinh Thi Bich Ty, Dinh Khac Hieu, Nguyen Thi My Tien, Nghiem My Ngoc, Le Manh Hung, Nguyen Thanh Dung, Tran Tan Thanh, Nguyen Thanh Truong, Guy Thwaites, Le Van Tan
Journal: Journal of Infection (2020)
Support Indigenous food system biocultural diversity
Authors: Alejandro Argumedo, Yiching Song, Colin K Khoury, Danny Hunter, Hannes Dempewolf
Journal: The Lancet Planetary Health (2020)

The Comment by Carol Zavaleta-Cortijo and colleagues1 was timely in emphasising the challenges faced by Indigenous peoples due to the combined effects of climate change, COVID-19, and longstanding inequities. Although pressure on Indigenous livelihoods is nothing new, current effects are extreme, both in terms of deaths due to the virus and disruptions to lifeways, including Indigenous food systems.
Replay bursts in humans coincide with activation of the default mode and parietal alpha networks
Authors: Cameron Higgins, Yunzhe Liu, Diego Vidaurre, Zeb Kurth-Nelson, Ray Dolan, Timothy Behrens, Mark Woolrich
Journal: Neuron (2020)

Our brains at rest spontaneously replay recently acquired information, but how this process is orchestrated to avoid interference with ongoing cognition is an open question. Here we investigated whether replay coincided with spontaneous patterns of whole-brain activity. We found, in two separate datasets, that replay sequences were packaged into transient bursts occurring selectively during activation of the default mode network (DMN) and parietal alpha networks. These networks are believed to support inwardly oriented attention and inhibit bottom-up sensory processing and were characterized by widespread synchronized oscillations coupled to increases in high frequency power, mechanisms thought to coordinate information flow between disparate cortical areas. Our data reveal a tight correspondence between two widely studied phenomena in neural physiology and suggest that the DMN may coordinate replay bursts in a manner that minimizes interference with ongoing cognition.
FRI0030 Treatment with etoricoxib (mk-0663), a cox-2 selective inhibitor, resulted in maintenance of clinical improvement in rheumatoid arthritis
Authors: SP Curtis, J Maldonado-Cocco, BR Losada, AE Gallagher, J Ng, S Mukhopadhyay, BJ Gertz
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Prostanoid synthesis is catalysed by two distinct cyclooxygenase (COX) isoforms; COX-1 (constitutive) and COX-2 (inducible). NSAIDs such as aspirin, ibuprofen and indomethacin inhibit both COX isoforms. Etoricoxib has been characterised as a COX-2 selective inhibitor with doses up to 150 mg QD (100-fold selective in human whole blood assay). <h3>Objectives</h3> Characterise the clinically active dose range and the longer term efficacy of etoricoxib in rheumatoid arthritis (RA). <h3>Methods</h3> Double-blind, randomised, placebo-controlled study conducted in 54 centres worldwide in 581 RA patients. Following withdrawal of prestudy NSAIDs and demonstration of a worsening of disease activity, eligible patients were randomised to once daily oral therapy with either placebo (n = 123), etoricoxib 10 mg (n = 78), 60 mg (n = 126), 90 mg (n = 134), or 120 mg (n = 120) and assessed after 2, 4 and 8 weeks. <h3>Results</h3> Over the initial 8-week period (Part I), patients taking etoricoxib 90 mg and 120 mg demonstrated similar efficacy, with both treatment groups showing significant improvements compared to placebo (average change from baseline p &lt; 0.05) for the primary endpoints of patient and investigator global assessment of disease activity and key secondary endpoints of patient global assessment of pain and Stanford Health Assessment Questionnaire (HAQ) Disability Index. For the patient assessment of disease activity, there was -9.41, and -9.15 mm (VAS) mean difference vs. placebo (least-squares mean difference vs. placebo, responses averaged over weeks 2 to 8 for the 90 mg, and 120 mg etoricoxib treatment groups, respectively). Data demonstrating that longer term efficacy was maintained (up to 52 weeks) will be presented. Etoricoxib was generally well-tolerated during Part I. There were no statistically significant trends for patients with one or more adverse events (AEs), serious AEs, drug-related serious AEs, or discontinuations due to AEs (p &gt; 0.05, etoricoxib vs placebo). Safety (up to 52 weeks) was generally consistent with that observed during Part I. <h3>Conclusion</h3> Etoricoxib 90–120 mg improved the symptoms of RA over 8 weeks and was well tolerated, with longer term efficacy data demonstrating maintenance of effect. Replicative phase III studies are ongoing to evaluate the efficacy and safety of etoricoxib in patients with RA.
Calcium and C-Reactive Protein: Hot Enough to Predict the Future?⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.
Authors: Christian W. Hamm, Holger M. Nef, Andreas Rolf, Helge Möllmann
Journal: Journal of the American College of Cardiology (2011)
Parallels Between the Antiviral State and the Irradiated State
Authors: Heather M McGee, Ariel E Marciscano, Allison M Campbell, Arta M Monjazeb, Susan M Kaech, John R Teijaro
Journal: JNCI Journal of the National Cancer Institute (2020)

Improved understanding of host antiviral defense and antitumor immunity have elucidated molecular pathways important to both processes. During viral infection, RNA or DNA in the host cell serves as a danger signal that initiates the antiviral response. Recent studies have elucidated similarities in the signaling pathways activated by viruses and the signaling pathways induced by tumor DNA that is released into the cytoplasm of irradiated tumor cells. Both the host defense to viral infection and the sterile inflammation provoked by radiotherapy induce a type I interferon response that is necessary for pathogen control and immune-mediated tumor control, respectively. These findings have led to the hypothesis that radiotherapy employs a form of viral mimicry.
152P ARID1A deficiency in EBV-positive gastric cancer is partially regulated by EBV-encoded miRNAs, but not by DNA promotor hypermethylation
Authors: K. Kase, M. Saito, L. Yamada, S. Nakajima, M. Ashizawa, Y. Kanke, H. Hanayama, H. Onozawa, H. Okayama, H. Endo, S. Fujita, W. Sakamoto, Z. Saze, T. Momma, K. Mimura, S. Ohki, K. Kono
Journal: Annals of Oncology (2020)
Immunogenic-cell-killing and immunosuppression-inhibiting nanomedicine
Authors: Ying Wang, Di Gao, Yan Liu, Xiaoqing Guo, Shuojia Chen, Li Zeng, Jinxuan Ma, Xingcai Zhang, Zhongmin Tian, Zhe Yang
Journal: Bioactive Materials (2020)

Combining chemo-therapeutics with immune checkpoint inhibitors facilitates killing cancer cells and activating the immune system through inhibiting immune escape. However, their treatment effects remain limited due to the compromised accumulation of both drugs and inhibitors in certain tumor tissues. Herein, a new poly (acrylamide-co-acrylonitrile-co-vinylimidazole-co-bis(2-methacryloyl) oxyethyl disulfide) (PAAVB) polymer-based intelligent platform with controllable upper critical solution temperature (UCST) was used for the simultaneous delivery of paclitaxel (PTX) and curcumin (CUR). Additionally, a hyaluronic acid (HA) layer was coated on the surface of PAAVB NPs to target the CD44-overexpressed tumor cells. The proposed nanomedicine demonstrated a gratifying accumulation in tumor tissue and uptake by cancer cells. Then, the acidic microenvironment and high level of glutathione (GSH) in cancer cells could spontaneously decrease the UCST of polymer, leading to the disassembly of the NPs and rapid drug release at body temperature without extra-stimuli. Significantly, the released PTX and CUR could induce the immunogenic cell death (ICD) to promote adaptive anti-tumor immunogenicity and inhibit immunosuppression through suppressing the activity of indoleamine 2,3-dioxygenase 1 (IDO1) enzyme respectively. Therefore, the synergism of this intelligent nanomedicine can suppress primary breast tumor growth and inhibit their lung metastasis.
Prevalence and incidence of injuries in para athletes: a systematic review with meta-analysis and GRADE recommendations
Authors: Larissa Santos Pinto Pinheiro, Juliana Melo Ocarino, Fernanda Oliveira Madaleno, Evert Verhagen, Marco Túlio de Mello, Maicon Rodrigues Albuquerque, André Gustavo Pereira Andrade, Carla Patrícia da Mata, Rafael Zambelli Pinto, Andressa Silva, Renan Alves Resende
Journal: British Journal of Sports Medicine (2020)

Objective To investigate prevalence, incidence and profile of musculoskeletal injuries in para athletes. Design Systematic review. Data sources Searches were conducted in MEDLINE, EMBASE, AMED, SPORTSDiscus, CINAHL and hand searching. Eligibility criteria Studies were considered if they reported prevalence or incidence of musculoskeletal injuries in para athletes. Study selection, data extraction and analysis followed the protocol. Meta-analyses were conducted to estimate the prevalence and incidence rate among studies and subgroup analyses investigated whether methodological quality and sample size of the studies influenced on the estimated injury prevalence and incidence. The Grading of Recommendations Assessment, Development and Evaluation system determined the strength of evidence. Results Forty-two studies were included. The prevalence of musculoskeletal injuries was 40.8% (95% CI 32.5% to 49.8%). Because of imprecision, indirectness and inconsistency, the strength of evidence was very low quality. The incidence of musculoskeletal injuries was 14.3 injuries per 1000 athlete-days (95% CI 11.9 to 16.8). The strength of evidence was low quality because of imprecision and indirectness. The subgroup analyses revealed that the sample size influenced on estimated injury prevalence and methodological quality influenced on estimated incidence. Injuries were more prevalent in the shoulder, for non-ambulant para athletes, and in the lower limbs, for ambulant para athletes. Summary/conclusion Para athletes show high prevalence and incidence of musculoskeletal injuries. Current very low-quality and low-quality evidence suggests that future high-quality studies with systematic data collection, larger sample size and specificities of para athletes are likely to change estimates of injury prevalence and incidence in para athletes. PROSPERO registration number CRD42020147982.
Impact of the COVID-19 pandemic on testing services for HIV, viral hepatitis and sexually transmitted infections in the WHO European Region, March to August 2020
Authors: Daniel Simões, Annemarie Rinder Stengaard, Lauren Combs, Dorthe Raben
Journal: Eurosurveillance (2020)

We present preliminary results of a coronavirus disease (COVID-19) impact assessment on testing for HIV, viral hepatitis and sexually transmitted infections in the WHO European Region. We analyse 98 responses from secondary care (n = 36), community testing sites (n = 52) and national level (n = 10). Compared to pre-COVID-19, 95% of respondents report decreased testing volumes during March-May and 58% during June-August 2020. Reasons for decreases and mitigation measures were analysed.
A portable scanner for magnetic resonance imaging of the brain
Authors: Clarissa Z. Cooley, Patrick C. McDaniel, Jason P. Stockmann, Sai Abitha Srinivas, Stephen F. Cauley, Monika Śliwiak, Charlotte R. Sappo, Christopher F. Vaughn, Bastien Guerin, Matthew S. Rosen, Michael H. Lev, Lawrence L. Wald
Journal: Nature Biomedical Engineering (2020)
Abstract PO-056: Role of the metabolite N-acetylaspartate in breast cancer progression
Authors: Akhila Balasubramanian, Weijie Zhang, Franklin Gu, Chandra Ambati, Nagireddy Putluri, Xiang Zhang, Aryan Namboodiri, Stefan Ambs, Arun Sreekumar
Journal: Cancer Research (2020)

Abstract Breast cancer (BCa) is a disease that affects over a quarter million women in the US every year. Our laboratory studies reprogrammed energy metabolism in BCa, which is an essential hallmark of the disease. Specifically, we focus on the metabolic rewiring events that occur in BCa, intending to identify cancer-associated metabolic vulnerabilities to treat this aggressive disease. Using a global metabolic profiling approach, we have determined that the metabolite N-acetylaspartate (NAA) is highly accumulated in patients with BCa. Prior studies involving NAA in other cancer types have attributed its accumulation to the upregulation of the enzyme N-acetyl transferase (NAT8L), which synthesizes NAA. However, using matched gene expression data, we found that the accumulation of NAA in these BCa tumors rather coincides with the downregulation of aspartoacylase (ASPA), the enzyme that breaks down NAA. To determine the role of NAA in BCa progression, we generated multiple cell line models containing either NAT8L knockdown, ASPA overexpression, or a combination of the two in the cell line MDA-MB231 in a bid to deplete intracellular NAA. We used these models to test for metastasis by tail vein injection in immunocompromised mice. Consistent with our expectations and other reports, NAT8L knockdown resulted in reduced lung metastasis. Interestingly, however, NAA depletion via ASPA overexpression increased metastasis to the lung in vivo. Furthermore, the combination of ASPA overexpression with the knockdown of NAT8L led to a moderate phenotype between the two independent genetic modifications. Our findings of the metastasis-promoting effect of NAA depletion via ASPA overexpression leads to us believe that it is not just the accumulation of NAA but also its utilization that is important for breast cancer progression. Our future experiments are directed towards determining how NAA utilization causes a pro-tumorigenic phenotype. We would also like to study the current inconsistency between ASPA transcript levels in patient tumors and its observed tumor-promoting function in xenograft experiments. Completion of these studies will potentially define the importance of elevated NAA levels in the context of aggressive BCa. Since NAA is a metabolite that can be detected in serum, our study could also lead to the development of NAA as a non-invasive biomarker for early detection of aggressive BCa, thus providing a bigger window for therapeutic intervention. Citation Format: Akhila Balasubramanian, Weijie Zhang, Franklin Gu, Chandra Ambati, Nagireddy Putluri, Xiang Zhang, Aryan Namboodiri, Stefan Ambs, Arun Sreekumar. Role of the metabolite N-acetylaspartate in breast cancer progression [abstract]. In: Abstracts: AACR Special Virtual Conference on Epigenetics and Metabolism; October 15-16, 2020; 2020 Oct 15-16. Philadelphia (PA): AACR; Cancer Res 2020;80(23 Suppl):Abstract nr PO-056.
17789 An antioxidant cocktail–containing cosmetic product (Liftactive Cure) prevents air pollution–induced skin hyperpigmentation: Results from the ex vivo Düsseldorf Pollution Skin Test
Authors: Jean Krutmann, Susanne Grether-Beck, Audrey Valois, Heidemarie Brenden, Ingo Uthe, Ingo Felsner, Heidemarie Brenden, Delphine Kerob
Journal: Journal of the American Academy of Dermatology (2020)
Abstract 13152: Endothelial Foxp1 Regulates Cardiac Fibrosis via Endothelial-To-Mesenchymal Transition
Authors: Jie Liu, Tao Zhuang, Xiaoli Chen, Yashu Kuang, Yanfang Wang, Lin Zhang, Yuzhen Zhang
Journal: Circulation (2019)

Introduction: Pathological cardiac fibrosis is a common feature of left ventricular remodeling and often progresses towards heart failure. Endothelial-to-mesenchymal transition (EndoMT) was reporte...
Metabolic Consequences of Solid Organ Transplantation
Authors: Mamatha Bhat, Shirine E Usmani, Amirhossein Azhie, Minna Woo
Journal: Endocrine Reviews (2020)

Abstract Metabolic complications affect over 50% of solid organ transplant recipients. These include posttransplant diabetes, nonalcoholic fatty liver disease, dyslipidemia, and obesity. Preexisting metabolic disease is further exacerbated with immunosuppression and posttransplant weight gain. Patients transition from a state of cachexia induced by end-organ disease to a pro-anabolic state after transplant due to weight gain, sedentary lifestyle, and suboptimal dietary habits in the setting of immunosuppression. Specific immunosuppressants have different metabolic effects, although all the foundation/maintenance immunosuppressants (calcineurin inhibitors, mTOR inhibitors) increase the risk of metabolic disease. In this comprehensive review, we summarize the emerging knowledge of the molecular pathogenesis of these different metabolic complications, and the potential genetic contribution (recipient +/− donor) to these conditions. These metabolic complications impact both graft and patient survival, particularly increasing the risk of cardiovascular and cancer-associated mortality. The current evidence for prevention and therapeutic management of posttransplant metabolic conditions is provided while highlighting gaps for future avenues in translational research.
Neonatal Pemphigus Vulgaris
Authors: Mallory L. Foster, Robert T. Spaulding, Courtney R. Schadt
Journal: JAMA Dermatology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal